RxDoctor Payments Data

William Mosier, MD

Ophthalmology · Fullerton, CANPI 1063553378

Payments from drug & device makers

$3,757in general payments, 2019–2025

Across 225 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sun Pharmaceutical Industries Inc.$1K
  • AbbVie$1K
  • Amgen$195
  • Dompe US, Inc.$190
  • Alcon$179
  • Oyster Point Pharma, Inc.$116
  • plus $634 from 12 others

What the payments were for

  • Food & beverage$3,71199%
  • Entertainment$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,757 in reported general payments places this provider in the 65th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$262,841
Medicare patients
905
Services billed
2,774

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost254$166,528
RhopressaNetarsudil Mesylate75$52,031
VyzultaLatanoprostene Bunod56$36,107
Alphagan PBrimonidine Tartrate75$34,915
Timolol Maleate632$28,863
Latanoprost1,589$26,882
RocklatanNetarsudil Mesylat/Latanoprost40$26,675
Brimonidine Tartrate278$16,155
RestasisCyclosporine16$15,118
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol62$12,456
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat615$10,847
Brinzolamide51$9,234
SimbrinzaBrinzolamide/Brimonidine Tart25$8,537
Prednisolone Acetate224$6,628
Travoprost25$5,918

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Alphagan P, Restasis, Combigan$1,030$220,428356 claims
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$31$78,705115 claims
Bausch & Lomb Americas Inc.Vyzulta$92$36,10756 claims
AlconSimbrinza$179$8,53725 claims
NovartisTravatan Z$44$5,21913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Fullerton

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →